Ventripoint and Ryerson University Have Been Approved for Government Funding to Advance Artificial Intelligence in Medical Imaging
Toronto, Ontario, March 26, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce its participation in a Natural Sciences and Engineering Research Council (NSERC) Engage grant for the development of automatic detection of all four chambers of the heart in echocardiographic views using artificial intelligence (AI), which will reduce time spent on analysis and training costs, and improve accuracy and comparability.
The NSERC funding has enabled us to partner with a top researcher at Ryerson University’s Department of Computer Science, Dr. Konstantinos Derpanis, on a project to further advance the Al capabilities that are already imbedded in our VMS+™ products. “This is very exciting for Ventripoint and the healthcare community at large because it allows us to bring new technology to market that will ultimately improve clinical outcomes and reduce overall cost of care,” said Desmond Hirson, President of Ventripoint.
The further development of such technologies is consistent with Ventripoint’s corporate mission of being a leader in providing medical products that use AI to enhance the productivity, accuracy and consistency of cardiac measurements. The benefits of this technology can also be extended to other modalities and imaging technologies, such as MRI and CT, to further expand the use of AI in the field of Medical Imaging.
Ryerson University is Canada’s leader in innovative, career-oriented education. Urban, culturally diverse and inclusive, the university is home to more than 43,000 students, including 2,600 Masters and PhD students, 3,100 faculty and staff, and nearly 185,000 alumni worldwide. For more information, visit www.ryerson.ca.
NSERC invests over $1.2 billion each year in natural sciences and engineering research in Canada. Its investments deliver discoveries – valuable world-firsts in knowledge claimed by a brain trust of over 11,000 professors. Investments enable partnerships and collaborations that connect industry with discoveries and the people behind them. Researcher-industry partnerships established by NSERC help inform research and development and solve scale-up challenges.
NSERC also provides scholarships and hands-on training experience for more than 30,000 post-secondary students and post-doctoral fellows. These young researchers will be the next generation of science and engineering leaders in Canada.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.